Загрузка...
Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
SUMMARY: Durvalumab is a programmed cell death ligand 1 inhibitor, which is now approved in Australia for use in non-small-cell lung and urothelial cancers. Autoimmune diabetes is a rare immune-related adverse effect associated with the use of immune checkpoint inhibitor therapy. It is now being inc...
Сохранить в:
| Опубликовано в: : | Endocrinol Diabetes Metab Case Rep |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Bioscientifica Ltd
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935712/ https://ncbi.nlm.nih.gov/pubmed/31829972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-19-0098 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|